Henlius Reports the NMPA’s Acceptance of IND for HLX14 (biosimilar, denosumab)

 Henlius Reports the NMPA’s Acceptance of IND for HLX14 (biosimilar, denosumab)

Henlius Reports the NMPA’s Acceptance of IND for HLX14 (biosimilar, denosumab)

Shots:

  • The NMPA has accepted the IND for HLX14, a biosimilar referencing Prolia, indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture
  • HLX14 is developed in harmony with biosimilar guidelines and was highly similar to the reference product in preclinical pharmacology, toxicology and PK studies
  • Henlius has a robust biosimilar portfolio which includes HLX01 (the first approved biosimilar in China) and HLX03 (adalimumab, biosimilar) & HLX02 (trastuzumab, biosimilar) which are currently under NMPA’s priority review. The development of HLX14 will boost Henlius’ portfolio to cover multiple disease areas

Click here ­to­ read full press release/ article | Ref: Henlius | Image: South China Morning Post

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post